Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2614 • ACR Convergence 2025
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Charles Peterfy, MD, PhD¹, John Tesser², Yaakov Levine³, Melissa Evangelista⁴, Vibeke Strand⁵, Michael Weinblatt⁶ and David Chernoff⁷, ¹Spire Sciences, Inc., Boca Raton, FL, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³SetPoint Medical, Valencia, CA, ⁴SetPoint Medical Corporation, Valencia, CA, ⁵Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Previously reported results from RESET-RA (ClinicalTrials.gov, NCT04539964) showed neuroimmune modulation via electrical stimulation of the left vagus nerve using an implantable device to treat…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 2268 • ACR Convergence 2025
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Clementina López Medina¹, Rafaela Ortega-Castro², Francisco Jose Cepas³, Montserrat Robustillo-Villarino⁴, Andres Zuniga-Vera⁴, Ana Martinez-Feito⁵, Ester Costa-Moya⁶, Delia Taverner-Torrent⁶, Luis Sainz Comas⁷, Cesar Diaz-Torne⁷, Virginia Ruiz-Esquide⁸, Cynthia Rojas⁹, Lourdes Martin-de la Sierra Lopez¹⁰, Laura Jimenez-Rodriguez¹⁰, David Velasco-Sanchez¹⁰, Regina Fará Garcia¹¹, Antonio Juan-Mas¹², Marina soledad Moreno Garcia¹³, Ana Valeria Acosta Alfaro¹⁴, Santiago Muñoz¹⁵, Maria Martín López¹⁶, Raquel Zas¹⁷, FRANCISCO JAVIER GODOY NAVARRETE¹⁸, Isabel Anon Onate¹⁹, Fernando Ortiz-Márquez²⁰, Natalia Mena Vázquez²¹, Paula Estrada-Alarcón²², Jerusalén Calvo²³, Alejandro Escudero Contreras²³ and Chamaida Plasencia-Rodríguez²⁴, ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁵Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁶Hospital Sant Joan Reus, Reus, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Hospital Clinic, Barcelona, Spain, ¹⁰Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹¹Hospital Son Llàtzer, Palma, Spain, ¹²Son Llazter University Hospital, Madrid, Spain, ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁴Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁶Hospital ¹² de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁸Jaen University Hospital, Spain, Jaen, Spain, ¹⁹Hospital Universitario de Jaén, Jaén, Spain, ²⁰Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ²⁴Hospital Universitario La Paz, MADRID, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…
Abstract Number: 2252 • ACR Convergence 2025
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexander Peterson², Alexandra Schmidt², Katherine Wysham³, Aliyah Pabani⁴, Carolyn Presley⁵, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁶, Ariela Orkaby⁷ and Namrata Singh¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Johns Hopkins, Washington, DC, ⁵Ohio State University Medical Center, Columbus, ⁶VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁷VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung…
Abstract Number: 2234 • ACR Convergence 2025
Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Cheuk Yin Tam, Ho So and Lai Shan Tam, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: This study compared the impact of achieving early sustained remission (sREM) versus early sustained low disease activity (sLDA) on patient-reported outcomes (PROs) after 5…
Abstract Number: 2104 • ACR Convergence 2025
Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A 1979 report by Huskisson, who developed the 0-10 pain visual analog scale (VAS) , entitled "Another look at osteoarthritis" indicated mean pain VAS…
Abstract Number: 1930 • ACR Convergence 2025
Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
Nelly Ziade¹, Karen Mechleb², Fatima Alnaimat³, Sherif Gamal⁴, Avin Maroof⁵, Bassel Elzorkany⁶, Manal Mashaleh⁷, Manal El Rakawi⁸, Mahmoud Adly⁹, Lina Elkibbi¹⁰, ERRAOUI Mariam¹¹, Krystel Aouad¹², Chafika Haouichat¹³, Nizar Abdullateef¹⁴, ASAL ADNAN RIDHA¹⁵, Fatemah Baron¹⁶ and Ihsane Hmamouchi¹⁷, ¹Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³The University of Jordan, amman, Jordan, ⁴Cairo University, Cairo, Egypt, ⁵University of Kurdistan Hawler, Erbil, Iraq, ⁶Private (BZRC), Cairo, Egypt, ⁷Al Saudi Hospital, Amman, Jordan, ⁸Djillali Bounaama University Hospital, Algiers, Algeria, Algiers, Algeria, ⁹Ministry of Health, Kuwait, Kuwait, Saad Elabdulla, Kuwait, ¹⁰Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ¹¹CHU Agadir, Agadir, Morocco, ¹²Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, ¹³Djillali Bounaama University Hospital, Algiers, Algeria, ¹⁴Baghdad College of Medicine, Baghdad, Iraq, ¹⁵Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁶Al-Jahra Hospital, Kuwait, Kuwait, Kuwait, Kuwait, ¹⁷Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco
Background/Purpose: Delayed diagnosis and treatment in chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA), is associated with…
Abstract Number: 1751 • ACR Convergence 2025
Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
Gregory McDermott¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Emily Kowalski⁵, Grace Qian⁶, Liya Sisay Getachew⁵, Kevin Mueller⁶, Alene Saavedra⁶, Lauren O'Keeffe⁶, Natalie Davis¹, Alison Puri⁷, Kathleen Vanni⁶, Caleb Bolden⁸, Tina Mahajan⁹, Erica Mulcaire-Jones¹⁰, Neda Kortam¹¹, Pierre Antoine Juge¹², Tracy J. Doyle¹³, Marcy Bolster¹⁴, Kevin Deane¹⁵, Dinesh Khanna¹⁰, Bryant England⁹, Raul San Jose Estepar⁶, George Washko⁶ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, ⁷Boston University, Brookline, MA, ⁸Massachusetts General Hospital, Boston, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Michigan, Ann Arbor, ¹²Hopital Bichat, APHP, Paris, France, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Massachusetts General Hospital, Concord, MA, ¹⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect…
Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Task Toyoda¹, Kerem Abacar¹, Farag Shuweihdi², Megan Sheridan³, Jacqueline Nam³, Ai Lyn Tan⁴, Lesley-Anne Bissell³, Paul Emery⁵ and Kulveer Mankia⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ²Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ⁵University of Leeds, Leeds, England, United Kingdom
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Rebecca Blank¹, Kevin Bu², Xinyuan Zhang³, Weixi Chen⁴, Ian Cunningham⁴, jeremy sokolove⁵, Lauren Lahey⁶, Adriana Heguy⁴, Rhina Medina⁴, Carles Ubeda⁷, Renuka Nayak⁸, Jiyuan Hu⁴, Adam Cantor⁹, Jakleen Lee⁹, Frances Williams¹⁰, Jose Clemente² and Jose Scher¹¹, ¹NYU Langone Health, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Kings College London, London, United Kingdom, ⁴NYU Grossman School of Medicine, New York, ⁵odyssey, Berwyn, PA, ⁶Stanford, Palo Alto, ⁷Fisabio, Madrid, ⁸University of California, San Francisco (UCSF), San Francisco, CA, ⁹Icahn School of Medicine, New York, ¹⁰Kings College London, London, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…
Abstract Number: 1322 • ACR Convergence 2025
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
Sara Salas Santamaría¹, Marta Chao Moreira², Manuel Juárez³, Marta Novella-Navarro², Pilar Nozal², Ana Martínez², Carolina Tornero⁴, Cristina Bohorquez⁵, Ana Sánchez², Carmen Cámara², Eduardo López², Eugenio de Miguel² and Chamaida Plasencia-Rodríguez², ¹Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵La Paz University Hospital, Alcalá De Henares, Spain
Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
Abstract Number: 1307 • ACR Convergence 2025
Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)
Martha Belury¹, Rachel Cole¹, Steven Pan² and Beatriz Hanaoka², ¹Ohio State University, Columbus, OH, ²Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: Rheumatoid arthritis (RA) patients have higher body fat percentages, particularly in the abdominal region, which is associated with increased systemic inflammation. Obesity is associated…
Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…

« Previous Page
1
…
7
8
9
10
11
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].